News & Updates

Long-term treatment with secukinumab, either at low or high dose, results in sustained efficacy and better health-related quality of life up to 4 years in children and adolescents with moderate-to-severe chronic plaque psoriasis, as shown in a phase III study presented at EADV 2024.

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

SB17, a proposed ustekinumab (UST) biosimilar, demonstrates comparable efficacy, safety, and pharmacokinetics (PK) to the reference drug, as well as lower immunogenicity up to week 28, among individuals suffering from moderate-to-severe psoriasis, according to a study.